Erlotinib, cabozantinib, or erlotinib plus cabozantinib as second- or third-line treatment of patients with EGFR wild-type advanced non-small cell lung cancer (ECOG-ACRIN 1512): a phase 2 randomised controlled trial

BACKGROUND: Erlotinib is approved for the treatment of all patients with advanced non-small cell lung cancer (NSCLC), but is most active in the treatment of EGFR mutant NSCLC. Cabozantinib, a small molecule tyrosine kinase inhibitor, targets MET, VEGFR, RET, ROS1, and AXL, which are implicated in lu...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Lancet Oncol
Main Authors: Neal, Joel W., Dahlberg, Suzanne E., Wakelee, Heather A., Aisner, Seena C., Bowden, Michaela, Huang, Ying, Carbone, David P., Gerstner, Gregory J., Lerner, Rachel E., Rubin, Jerome L., Owonikoko, Taofeek K., Stella, Philip J., Steen, Preston D., Khalid, Ahmed Ali, Ramalingam, Suresh S.
Formato: Artigo
Idioma:Inglês
Publicado em: 2016
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5154681/
https://ncbi.nlm.nih.gov/pubmed/27825638
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1470-2045(16)30561-7
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados